Gilead Sciences (NASDAQ:GILD) reported quarterly earnings of $1.37 per share which missed the analyst consensus estimate of $1.54。 The company reported quarterly sales of $6.35 billion which beat the analyst consensus estimate of $6.33 billion。
Mizuho analyst Anthony Petrone maintains Intuitive Surgical (NASDAQ:ISRG) with a Neutral and raises the price target from $240 to $250.
Mizuho raised Intuitive Surgical (NASDAQ:ISRG) price target from $240 to $250 Read Post »
Raymond James analyst Jason Bednar maintains Intuitive Surgical (NASDAQ:ISRG) with a Outperform and raises the price target from $270 to $323.
Raymond James raised Intuitive Surgical (NASDAQ:ISRG) price target from $270 to $323 Read Post »
Barclays Maintained Intuitive Surgical (NASDAQ:ISRG) “Overweight” rating and Raises its price target to $314.00 From $298.00.
Barclays Raised Intuitive Surgical (NASDAQ:ISRG) price target to $314.00 Read Post »
Morgan Stanley analyst David Phung maintains Eli Lilly (NYSE:LLY) with a Overweight and lowers the price target from $448 to $445.
Morgan Stanley lowered Eli Lilly (NYSE:LLY) price target to $445 Read Post »
Raymond James analyst John Ransom maintains UnitedHealth Group (NYSE:UNH) with a Strong Buy and maintains $630 price target.
Raymond James maintained UnitedHealth Group (NYSE:UNH) $630 price target Read Post »
Analyst Forecast UnitedHealth Group (NYSE:UNH) reported Q1 2023 adjusted earnings of $6.26 per diluted share, up from $5.49 per share a year earlier. Analysts polled by Capital IQ expected adjusted EPS of $6.08. Revenue for the quarter ended March 31 was $91.93 billion, up from $80.15 billion a year ago. Analysts surveyed by Capital IQ expected $89.78 billion. The company said it expects 2023 adjusted EPS of $24.50 to $25. Analysts polled by Capital IQ are projecting adjusted EPS of $24.93. Financian Revenues of $91.9 Billion, Grew 15% Year-Over-Year Earnings from Operations Grew 16% Cash Flows from Operations were $16.3 Billion; Adjusted Cash Flows from Operations were $5.1 Billion Earnings were $5.95 Per Share, Adjusted Earnings $6.26 Per Share Earnings Guidance The company increased its full year net earnings outlook to $23.25 to $23.75 per share and adjusted net earnings to $24.50 to $25.00 per share. Share Repurchase The company
Guggenheim analyst Seamus Fernandez maintains Merck & Co (NYSE:MRK) with a Buy and raises the price target from $123 to $124.
Guggenheim raised Merck & Co (NYSE:MRK) price target to $124 Read Post »
Deutsche Bank Resumes Coverage of CVS Health (NYSE:CVS) With Hold Rating, $87 Price Target.
Deutsche Bank announced CVS Health (NYSE:CVS) $87 Price Target Read Post »
Morgan Stanley analyst Terence Flynn maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $178 to $181.
Morgan Stanley raised AbbVie (NYSE:ABBV) price target to $181 Read Post »
Morgan Stanley analyst Terence Flynn maintains Johnson & Johnson (NYSE:JNJ) with a Equal-Weight and lowers the price target from $180 to $179.
Morgan Stanley lowered Johnson & Johnson (NYSE:JNJ) price target to $179 Read Post »
Morgan Stanley analyst Terence Flynn maintains Pfizer (NYSE:PFE) with a Equal-Weight and lowers the price target from $45 to $44.
Morgan Stanley lowered Pfizer (NYSE:PFE) price target to $44 Read Post »